Are growth-hormone secretagogue peptides legal to buy in Australia?

It depends entirely on the specific compound and its regulatory status. Compounds listed on the Australian Register of Therapeutic Goods (ARTG) with an approved indication may be legally accessed via a prescription from a licensed practitioner. Many GHS peptides circulating in fitness and wellness contexts have no ARTG entry and no approved indication — supplying these without TGA approval is illegal under the Therapeutic Goods Act 1989, and the TGA is actively enforcing against this.

What is the difference between GHSR agonists and GHRH analogues?

Both classes stimulate growth-hormone release but act at different receptors. GHSR agonists (ghrelin receptor agonists) bind to the growth-hormone secretagogue receptor (GHSR-1a), mimicking ghrelin. GHRH analogues act on the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs. The downstream effect — increased pulsatile GH secretion — is broadly similar, but the receptor pharmacology, tissue expression patterns, and associated signalling differ meaningfully between the two.

Can a doctor prescribe a GHS compound in Australia?

In some circumstances, yes. Where no ARTG-listed product exists but a compound meets criteria, a medical practitioner may apply to access it through the Special Access Scheme (SAS) or, for more frequent use, under an Authorised Prescriber arrangement with TGA approval. These are regulated medical pathways involving clinical assessment and oversight — they are not available for general or non-clinical use.

Why are most GHS peptides injected rather than taken orally?

Peptide structures — chains of amino acids joined by peptide bonds — are efficiently broken down in the gastrointestinal tract by proteolytic enzymes, and those that survive GI degradation often face extensive first-pass metabolism in the liver. Subcutaneous injection bypasses both of these barriers, making it the predominant administration route in research settings for peptide GHS compounds. Developing orally bioavailable small-molecule secretagogues has been one avenue of research partly motivated by this limitation.

What does GMP certification mean for peptide compounds?

Good Manufacturing Practice (GMP) is a set of quality standards — enforced by the TGA in Australia — that govern how therapeutic goods are manufactured, tested, and controlled. For peptide compounds, GMP certification provides assurance around purity, potency, sterility, and the absence of harmful contaminants. Compounds produced outside GMP-certified facilities carry significant uncertainty about their actual composition, which matters both for safety and for interpreting any research data that used pharmaceutical-grade material.

Growth-Hormone Secretagogues (regulatory overview)

By Priya Nandakumar · 12 May 2026 · 7 min read

Colorful abstract art of organic-shaped forms.

Growth-hormone secretagogues: what they are and where they sit under Australian law

Forty-three peptide-related enforcement actions. That's how many the TGA flagged in a single compliance sweep reported in their 2022–23 regulatory activity summary , and growth-hormone secretagogues (GHS) were among the most frequently cited classes. I keep that number pinned to my monitor, honestly, because it tells you something important about the gap between how these molecules are discussed online and how they're actually regulated here.

So let's close that gap.

What growth-hormone secretagogues actually are

A growth-hormone secretagogue is any compound that stimulates the pituitary gland to release endogenous growth hormone (GH). The term covers a chemically diverse group , some are peptides, some are small molecules, and a few sit in between.

The unifying mechanism is interaction with either the growth-hormone secretagogue receptor (GHSR-1a, also called the ghrelin receptor) or the growth-hormone-releasing hormone receptor (GHRHR). Ghrelin itself, a 28-amino acid acylated peptide produced mainly in the stomach, is the endogenous ligand for GHSR-1a. Most synthetic GHS compounds were developed as ghrelin mimetics , designed to bind the same receptor with varying selectivity and half-life.

The peptide-based members of this class are chains of amino acids joined by peptide bonds. That structure matters for pharmacokinetics: peptides are generally degraded rapidly in the GI tract, which is why most GHS compounds under investigation have been administered parenterally; often by subcutaneous injection, in research settings.

A brief history of the class

The pharmacological story begins in the 1970s when Cyril Bowers at Tulane University identified synthetic enkephalin analogues that unexpectedly stimulated GH release. That was the first clue that a receptor-mediated pathway existed independent of GHRH. Over the next two decades, iterative medicinal chemistry produced progressively more selective and potent GHSR agonists.

The discovery of ghrelin itself, published by Kojima et al. in Nature in 1999; reframed everything. Suddenly there was an endogenous ligand to explain the receptor the synthetic compounds had been hitting. From that point, research branched: one arm continued developing synthetic peptide GHSR agonists, another explored small-molecule (non-peptide) secretagogues that might have better oral bioavailability than their peptide counterparts. (Understanding bioavailability and first-pass metabolism is core to why the administration route matters so much for this class, first-pass hepatic degradation tends to destroy peptide structures efficiently.)

Several compounds advanced through Phase II and Phase III clinical trials primarily for cachexia and growth-hormone deficiency in specific populations, though the clinical development pipeline has had a mixed record, a number of programmes were discontinued after failing primary endpoints or encountering safety signals.

The Australian regulatory picture

This is where things get precise, and I want to be precise because I've seen a lot of vague hand-waving on this topic.

Under the Poisons Standard (the legislative instrument that sets scheduling in Australia), different GHS compounds fall into different schedules depending on their approval status. The broad framework:

Compounds with an approved indication and an entry on the Australian Register of Therapeutic Goods (ARTG) may be available as Schedule 4 (prescription-only) medicines via a licensed prescriber.
Some compounds with higher potential for misuse or narrower approved clinical windows may attract Schedule 8 (controlled drug) status, requiring additional prescriber and pharmacist record-keeping obligations.
Many of the peptide GHS compounds most discussed in fitness and wellness contexts; including several well-known synthetic GHSR agonists, have no ARTG entry and no current approved therapeutic indication in Australia. Supplying these without TGA approval is illegal under the Therapeutic Goods Act 1989.

The TGA has been direct about enforcement. Their published compliance position makes clear that the supply of unapproved peptides, including many growth-hormone secretagogue peptides marketed for body composition or recovery; constitutes a breach of the Act. Penalties include fines and, in serious cases, criminal prosecution. Supplying these substances without approval is illegal in Australia, and the TGA is actively enforcing.

Patients who have a genuine clinical need assessed by a specialist may, in some circumstances, access certain compounds via the Special Access Scheme (SAS) or through an Authorised Prescriber arrangement. These are regulated pathways involving medical oversight, they are not a workaround for general use.

Manufacturing quality and the GMP question

Even setting aside scheduling, there's a manufacturing quality dimension that deserves its own paragraph. Peptide synthesis requires precise chemistry and rigorous quality control. Compounds produced outside a Good Manufacturing Practice (GMP)-certified facility carry real uncertainty about purity, concentration, and contamination. Research on peptide GHS compounds has generally used pharmaceutical-grade material; extrapolating those findings to compounds of unknown provenance isn't scientifically valid.

I'd argue this is one of the more under-discussed regulatory gaps in how GHS peptides circulate in Australia. The scheduling question gets most of the oxygen, but the GMP question is just as serious from a safety standpoint, and much harder for any individual to assess without laboratory testing.

What clinical research actually shows (and its limits)

A handful of GHS compounds have accumulated meaningful clinical trial data. Research has investigated their effects on GH pulsatility, IGF-1 levels, sleep architecture, appetite regulation (given ghrelin's role in hunger signalling), and body composition in specific clinical populations; including adults with confirmed GH deficiency and patients with muscle-wasting conditions.

The honest read of that literature is: results in clinically defined populations, under controlled conditions with pharmaceutical-grade material, are not the same as results in healthy adults using unverified compounds bought outside regulated channels. The populations differ. The doses differ. The compound quality differs. Reporting on clinical findings without that caveat flattens important distinctions.

The National Institutes of Health's PubChem database and NCBI literature archives are the sensible starting point for anyone wanting to read primary sources on specific compounds; I'll link to NCBI below rather than citing individual compound names with outcomes attached, because the clinical status of specific compounds changes and I'd rather point you toward living databases than give you a snapshot that ages poorly.

Where GHS compounds sit in the broader peptide taxonomy

Growth-hormone secretagogues are one class within a much larger peptide landscape. The class is distinct from, say, GLP-1 receptor agonists, another peptide-based drug class with a more established Australian regulatory pathway, though both illustrate how peptide pharmacology has moved from niche biochemistry into mainstream clinical and regulatory attention relatively quickly.

Understanding the GHS class also requires keeping the receptor biology clear. GHSR-1a is a G-protein-coupled receptor with wide expression in the brain (particularly the hypothalamus and pituitary) as well as peripheral tissues. It's not a simple on/off switch; it shows constitutive activity (meaning it has some basal signalling even without a ligand), and different agonists produce different downstream signalling profiles. That receptor pharmacology is genuinely interesting, and it's part of why the class has attracted sustained research interest over several decades despite the mixed clinical development record.

Between episodes of my current true-crime podcast obsession, I went back through a few of the original Bowers papers this week. There's something almost archaeological about reading 1980s receptor pharmacology, the tools were so limited compared to what's available now, and yet the core observations have held up remarkably well. Anyway.

The short version on compliance

Growth-hormone secretagogues represent a pharmacologically well-characterised class with a legitimate clinical research history and a complicated regulatory reality in Australia. Some compounds have approved pathways; many do not. The TGA enforces against the supply of unapproved peptides in this class. GMP-certified manufacture is a separate and equally important quality standard. Legitimate access, where it exists, runs through prescribed medical channels, SAS, Authorised Prescriber, or ARTG-listed products; not through unregulated supply chains.

The chemistry is fascinating. The regulatory picture is, frankly, less ambiguous than some corners of the internet would have you believe.

Sources

, Priya Nandakumar, Pharmacology writer, peptides & PK

Common questions

Are growth-hormone secretagogue peptides legal to buy in Australia?: It depends entirely on the specific compound and its regulatory status. Compounds listed on the Australian Register of Therapeutic Goods (ARTG) with an approved indication may be legally accessed via a prescription from a licensed practitioner. Many GHS peptides circulating in fitness and wellness contexts have no ARTG entry and no approved indication — supplying these without TGA approval is illegal under the Therapeutic Goods Act 1989, and the TGA is actively enforcing against this.
What is the difference between GHSR agonists and GHRH analogues?: Both classes stimulate growth-hormone release but act at different receptors. GHSR agonists (ghrelin receptor agonists) bind to the growth-hormone secretagogue receptor (GHSR-1a), mimicking ghrelin. GHRH analogues act on the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs. The downstream effect — increased pulsatile GH secretion — is broadly similar, but the receptor pharmacology, tissue expression patterns, and associated signalling differ meaningfully between the two.
Can a doctor prescribe a GHS compound in Australia?: In some circumstances, yes. Where no ARTG-listed product exists but a compound meets criteria, a medical practitioner may apply to access it through the Special Access Scheme (SAS) or, for more frequent use, under an Authorised Prescriber arrangement with TGA approval. These are regulated medical pathways involving clinical assessment and oversight — they are not available for general or non-clinical use.
Why are most GHS peptides injected rather than taken orally?: Peptide structures — chains of amino acids joined by peptide bonds — are efficiently broken down in the gastrointestinal tract by proteolytic enzymes, and those that survive GI degradation often face extensive first-pass metabolism in the liver. Subcutaneous injection bypasses both of these barriers, making it the predominant administration route in research settings for peptide GHS compounds. Developing orally bioavailable small-molecule secretagogues has been one avenue of research partly motivated by this limitation.
What does GMP certification mean for peptide compounds?: Good Manufacturing Practice (GMP) is a set of quality standards — enforced by the TGA in Australia — that govern how therapeutic goods are manufactured, tested, and controlled. For peptide compounds, GMP certification provides assurance around purity, potency, sterility, and the absence of harmful contaminants. Compounds produced outside GMP-certified facilities carry significant uncertainty about their actual composition, which matters both for safety and for interpreting any research data that used pharmaceutical-grade material.